Patient characteristics
| Variable . | Imatinib . | Allo-HSCT . | P . |
|---|---|---|---|
| No. of patients | 87 | 45 | |
| Age, y | .000 | ||
| Median (range) | 44 (22-60) | 34 (10-59) | |
| Sex, no. (%) | .368 | ||
| Male | 51 (58.6) | 30 (66.7) | |
| Female | 36 (41.4) | 15 (33.3) | |
| CML duration, mo | .006 | ||
| Median (range) | 26 (.5-192) | 5 (2-80) | |
| Interval from CML diagnosis to AP, mo | .001 | ||
| Median (range) | 17 (0-191) | 2 (0-75) | |
| Interval from onset AP to treatment, mo | .063 | ||
| Median (range) | 1 (0-66) | 3 (1-11) | |
| Disease status at diagnosis of CML, no. (%) | .535 | ||
| AP | 19 (21.8%) | 12 (26.7%) | |
| CP | 68 (78.2%) | 33 (73.3%) | |
| Previous combined chemotherapy for AP, no. (%) | .000 | ||
| No | 53 (60.9) | 41 (91.1) | |
| Yes | 34 (39.1) | 4 (8.9) | |
| Splenomegaly, no. (%) | .314 | ||
| No | 58 (66.7) | 26 (57.8) | |
| Yes | 29 (33.3) | 19 (42.2) | |
| WBC count, × 109/L | .000 | ||
| Median (range) | 9 (1.2-238) | 30 (2-280) | |
| Hemoglobin, g/L | .764 | ||
| Median (range) | 112 (45-162) | 106.5 (53-152) | |
| Platelet count, × 109/L | .002 | ||
| Median (range) | 340 (13-2415) | 819 (18.5-2338) | |
| PB blasts, % | .285 | ||
| Median (range) | 0 (0-19) | 0 (0-13) | |
| PB basophils, % | .712 | ||
| Median (range) | 8 (0-56) | 10 (0-34) | |
| BM blasts, % | .103 | ||
| Median (range) | 3 (0-19) | 5.3 (0-18.5) | |
| AP features, no. (%) | |||
| Blasts ≥ 10% | 16 (18.4) | 12 (26.7) | .270 |
| Basophils ≥ 20% | 23 (26.4) | 7 (15.6) | .157 |
| Persistent thrombocytopenia | 13 (14.9) | 4 (8.9) | .325 |
| Persistent thrombocytosis | 12 (13.8) | 16 (35.6) | .004 |
| Increasing spleen size | 29 (33.3) | 19 (42.2) | .314 |
| Clonal evolution only | 10 (11.5) | 3 (6.7) | .541 |
| Hematologic features only | 49 (56.3) | 38 (84.4) | .001 |
| Both of the clonal evolution and hematologic features | 28 (32.2) | 4 (8.9) | .003 |
| Variable . | Imatinib . | Allo-HSCT . | P . |
|---|---|---|---|
| No. of patients | 87 | 45 | |
| Age, y | .000 | ||
| Median (range) | 44 (22-60) | 34 (10-59) | |
| Sex, no. (%) | .368 | ||
| Male | 51 (58.6) | 30 (66.7) | |
| Female | 36 (41.4) | 15 (33.3) | |
| CML duration, mo | .006 | ||
| Median (range) | 26 (.5-192) | 5 (2-80) | |
| Interval from CML diagnosis to AP, mo | .001 | ||
| Median (range) | 17 (0-191) | 2 (0-75) | |
| Interval from onset AP to treatment, mo | .063 | ||
| Median (range) | 1 (0-66) | 3 (1-11) | |
| Disease status at diagnosis of CML, no. (%) | .535 | ||
| AP | 19 (21.8%) | 12 (26.7%) | |
| CP | 68 (78.2%) | 33 (73.3%) | |
| Previous combined chemotherapy for AP, no. (%) | .000 | ||
| No | 53 (60.9) | 41 (91.1) | |
| Yes | 34 (39.1) | 4 (8.9) | |
| Splenomegaly, no. (%) | .314 | ||
| No | 58 (66.7) | 26 (57.8) | |
| Yes | 29 (33.3) | 19 (42.2) | |
| WBC count, × 109/L | .000 | ||
| Median (range) | 9 (1.2-238) | 30 (2-280) | |
| Hemoglobin, g/L | .764 | ||
| Median (range) | 112 (45-162) | 106.5 (53-152) | |
| Platelet count, × 109/L | .002 | ||
| Median (range) | 340 (13-2415) | 819 (18.5-2338) | |
| PB blasts, % | .285 | ||
| Median (range) | 0 (0-19) | 0 (0-13) | |
| PB basophils, % | .712 | ||
| Median (range) | 8 (0-56) | 10 (0-34) | |
| BM blasts, % | .103 | ||
| Median (range) | 3 (0-19) | 5.3 (0-18.5) | |
| AP features, no. (%) | |||
| Blasts ≥ 10% | 16 (18.4) | 12 (26.7) | .270 |
| Basophils ≥ 20% | 23 (26.4) | 7 (15.6) | .157 |
| Persistent thrombocytopenia | 13 (14.9) | 4 (8.9) | .325 |
| Persistent thrombocytosis | 12 (13.8) | 16 (35.6) | .004 |
| Increasing spleen size | 29 (33.3) | 19 (42.2) | .314 |
| Clonal evolution only | 10 (11.5) | 3 (6.7) | .541 |
| Hematologic features only | 49 (56.3) | 38 (84.4) | .001 |
| Both of the clonal evolution and hematologic features | 28 (32.2) | 4 (8.9) | .003 |
WBC indicates white blood cell; PB, peripheral blood; and BM, bone marrow